Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog

Ligand Pharmaceuticals Incorporated ( LGND ) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized. Shares of Ligand Pharma were up 2.93% following the announcement.

According to the deal, Ligand Pharma will receive an upfront payment along with potential milestone payments. Ligand Pharma is also entitled to revenues and royalties under the deal. This partnership has expanded Ligand's portfolio of Shots-on-Goal with more than 100 fully funded programs.

We are positive on the agreement between Ligand Pharma and Avion Pharmaceuticals.

Ligand Pharma has announced a number of deals this year including agreements with TG Therapeutics ( TGTX ) and Omthera Pharmaceuticals (treatment of dyslipidemia, including hypertriglyceridemia). Ligand Pharma has also licensed the rights to five programs to Viking Therapeutics.

The TG Therapeutics deal involves the development and commercialization of Ligand's interleukin-1 receptor associated kinase-4 (IRAK-4) inhibitors. Ligand Pharma is currently developing IRAK4 inhibitors for the treatment of certain forms of cancer and autoimmune diseases. The IRAK4 program is in pre-clinical development.

According to the deal, Ligand Pharma received 125,000 unregistered shares of TG Therapeutics' common stock, valued at about $1 million on the date of signing the deal. Additionally, the company will receive $207 million on the achievement of specific milestones and tiered royalties of 6%−9.5% on net sales of licensed products.

Ligand Pharma's Captisol technology has enabled six FDA approved products, which include Amgen's ( AMGN ) Kyprolis and Merck's Noxafil IV. Meanwhile, more than 30 Captisol enabled products are in clinical development.

Ligand Pharma holds a Zacks Rank #5 (Strong Sell). A better ranked stock in the biotech sector is Actelion Ltd. ( ALIOF ), carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMGEN INC (AMGN): Free Stock Analysis Report


LIGAND PHARMA-B (LGND): Free Stock Analysis Report

TG THERAPEUTICS (TGTX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More